|
|
|
|
|
Ibritumomab
drug data and news
Ibritumomab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ibritumomab | ||
| Brand Names/Synonyms | Ig gamma-2A chain C region, membrane-bound form; radiolabeled murine anti-CD20; Zevalin (IDEC Pharmaceuticals) | ||
| Indication | For treatment of non-Hodgkin's lymphoma | ||
| Sponsored links | Description | Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | |
| Pharmacology | Zevalin binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin’s lympohomas. The antibody leads to selective killing of B-cells. | ||
| Mechanism Of Action | Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. The chelate tiuxetan, which tightly binds radioactive In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells. | ||
| Ibritumomab News (When available) |
Biogen Idec Reports Full Year and Fourth Quarter 2005 Results Feb 15, 2006 ... Go to the Article Feb 13, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antineoplastic Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Murine anti-CD20 antibody | ||
| Chemical Formula | C6382H9830N1672O1979S54 >Mouse Anti-CD20 Light chain 1 >Mouse Anti-CD20 Heavy chain 1 >Mouse Anti-CD20 Light chain 1 | ||
| Molecular Weight | 143375.5 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.359 | ||
| Isoelectric Point | 7.91 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production | ||
| Half Life | 0.8 hours (mammalian reticulocytes, in vitro) | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic3/zevalin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00069 | ||
| CAS Registry Number | 174722-31-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | GCAM_MOUSE (P01865) | ||
| GenBank ID | J00470 | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |